Emergent BioSolutions Inc. 0IGA.L Stock
Emergent BioSolutions Inc. Price Chart
Emergent BioSolutions Inc. 0IGA.L Financial and Trading Overview
Emergent BioSolutions Inc. stock price | 2.06 USD |
Previous Close | 8.09 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 34.64 USD |
Volume | 3.8K USD |
Avg. Volume | 1.8K USD |
Market Cap | 3.57M USD |
Beta (5Y Monthly) | 0.929225 |
PE Ratio (TTM) | 0.027249746 |
EPS (TTM) | 2.97 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0IGA.L Valuation Measures
Enterprise Value | 1.39B USD |
Trailing P/E | 0.027249746 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.0036486357 |
Price/Book (mrq) | 0.33883744 |
Enterprise Value/Revenue | 1.417 |
Enterprise Value/EBITDA | -8.007 |
Trading Information
Emergent BioSolutions Inc. Stock Price History
Beta (5Y Monthly) | 0.929225 |
52-Week Change | -71.54% |
S&P500 52-Week Change | 20.43% |
52 Week High | 34.64 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 9.34 USD |
200-Day Moving Average | 14.89 USD |
0IGA.L Share Statistics
Avg. Volume (3 month) | 1.8K USD |
Avg. Daily Volume (10-Days) | 63 USD |
Shares Outstanding | 50.95M |
Float | 45.34M |
Short Ratio | N/A |
% Held by Insiders | 0.76% |
% Held by Institutions | 95.52% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -41.19% |
Operating Margin (ttm) | -32.18% |
Gross Margin | 10.62% |
EBITDA Margin | -17.70% |
Management Effectiveness
Return on Assets (ttm) | -6.86% |
Return on Equity (ttm) | -29.021% |
Income Statement
Revenue (ttm) | 978.5M USD |
Revenue Per Share (ttm) | 19.58 USD |
Quarterly Revenue Growth (yoy) | -46.30% |
Gross Profit (ttm) | 236.8M USD |
EBITDA | -173200000 USD |
Net Income Avi to Common (ttm) | -403100000 USD |
Diluted EPS (ttm) | 2.967 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 436.1M USD |
Total Cash Per Share (mrq) | 8.65 USD |
Total Debt (mrq) | 1.41B USD |
Total Debt/Equity (mrq) | 117.65 USD |
Current Ratio (mrq) | 1.005 |
Book Value Per Share (mrq) | 23.861 |
Cash Flow Statement
Operating Cash Flow (ttm) | -180800000 USD |
Levered Free Cash Flow (ttm) | -202887504 USD |
Profile of Emergent BioSolutions Inc.
Country | United Kingdom |
State | MD |
City | Gaithersburg |
Address | 400 Professional Drive |
ZIP | 20879 |
Phone | 240 631 3200 |
Website | https://www.emergentbiosolutions.com |
Industry | |
Sector(s) | |
Full Time Employees | 2500 |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Q&A For Emergent BioSolutions Inc. Stock
What is a current 0IGA.L stock price?
Emergent BioSolutions Inc. 0IGA.L stock price today per share is 2.06 USD.
How to purchase Emergent BioSolutions Inc. stock?
You can buy 0IGA.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Emergent BioSolutions Inc.?
The stock symbol or ticker of Emergent BioSolutions Inc. is 0IGA.L.
How many shares does Emergent BioSolutions Inc. have in circulation?
The max supply of Emergent BioSolutions Inc. shares is 441.58K.
What is Emergent BioSolutions Inc. Price to Earnings Ratio (PE Ratio)?
Emergent BioSolutions Inc. PE Ratio is 0.00694304 now.
What was Emergent BioSolutions Inc. earnings per share over the trailing 12 months (TTM)?
Emergent BioSolutions Inc. EPS is 2.97 USD over the trailing 12 months.